Palvella Therapeutics (PVLA) PT Raised to $120 at Oppenheimer, 'We're Buyers into Key Data'

Oppenheimer analyst Trevor Allred raised the price target on Palvella Therapeutics (NASDAQ: PVLA) to $120.00 (from $100.00) while maintaining a Outperform rating.

The analyst comments "Palvella reported a 3Q net loss of $11.3M vs our $10.3M estimate. Two key readouts are just ahead with their Phase 2 cutaneous venous (TOIVA) results next month, and Phase 3 microcystic LM data in 1Q26. We like the set-up beyond the two Phase 2 clinical initiations for both Qtorin rapamycin (angiokeratomas) and Qtorin pitavastatin (disseminated superficial actinic porokeratosis, DSAP) in 2H26. Qtorin's pipeline potential appears to be at the starting line."

You May Also Be Interested In

• York Space Systems (YSS) PT Lowered to $15 at Jefferies
• Parsons wins $665M Army contract for support services
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24